A Retrospective Analysis of Clinicopathological Data and outcomes of Hormonal Positive Her2 Negative Metastatic Breast Cancer Patients in Clinical Oncology Department in Ain Shams University Hospitals in Egypt, Ain Shams Clinical Oncology Registry (ASCOR)

Abstract

recent years, a significant evolution has occurred in the management hormone receptor-positive metastatic breast cancer patients. Given the emerging evidence, it is now essential to optimize therapy and to choose a treatment sequence strategy that considers both patient-and tumor-related factors. Many prognostic factors impact survival in patients with hormone receptor-positive Her2 negative advanced breast cancer. Treatment outcomes can vary considerably due to these factors. In the present study, many prognostic factors impacted survival such as age where younger patients had a worse prognosis, site of metastasis where liver and lung metastasis were associated with worse prognosis, as well as whether the patient had recurrent breast cancer or de novo stage IV breast cancer, where recurrent breast cancer patients had worse prognosis in comparison to de novo stage IV breast cancer patients. In general, endocrine therapy represents the mainstay for most patients with hormone receptor-positive me